BioNTech names new CEO as it pivots to cancer drugs

BioNTech, the Mainz-based company renowned for its COVID-19 vaccine, is set to welcome Guido Oelkers as its new chief executive officer. Oelkers, who has amassed over three decades of experience in the biotechnology and pharmaceutical sectors, will assume the role by February 1, 2025.

Oelkers joins BioNTech from Swedish Orphan Biovitrum (Sobi), where he served as CEO since 2017. His extensive background includes a tenure at Hoechst AG in the 1990s and a strong focus on bringing innovative products to market, particularly within the U.S. market.

This leadership transition coincides with a strategic pivot for BioNTech. While the company achieved significant financial success during the pandemic, it later faced financial losses. In May, BioNTech announced plans to close several production facilities, including sites in Idar-Oberstein and Marburg, as well as facilities of its acquired competitor Curevac, and a plant in Singapore. These measures could affect up to 1,860 jobs.

Company co-founder Ugur Sahin, along with his wife Özlem Türeci, had previously announced their intention to leave BioNTech by the end of 2026 to establish a new venture focused on next-generation mRNA-based medicines. They intend to remain shareholders in BioNTech. Sahin expressed confidence in Oelkers, describing him as a manager with a deep understanding of the pharmaceutical industry and strong strategic judgment, coupled with respect for the company's culture and employees. Sahin pledged his active support to ensure a smooth transition.

“

To ensure a smooth and successful transition, I will actively support his entry.